Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGENNASDAQ:LYELNASDAQ:THTXNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$0.33+12.0%$0.33$0.18▼$1.53$29.42M0.862.11 million shs979,451 shsLYELLyell Immunopharma$0.42+1.3%$0.51$0.39▼$2.88$124.34M-0.251.04 million shs463,724 shsTHTXTheratechnologies$2.76+0.5%$1.97$1.08▼$3.13$126.68M0.56799,915 shs383,922 shsTNXPTonix Pharmaceuticals$19.06+0.9%$17.54$6.76▼$672.00$122.62M1.63795,751 shs282,054 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen-8.52%-11.15%+3.93%-42.60%-74.91%LYELLyell Immunopharma-4.33%-3.80%-10.56%-32.95%-83.63%THTXTheratechnologies-0.72%-4.53%+85.14%+79.08%+120.97%TNXPTonix Pharmaceuticals-3.58%+8.51%+20.72%+26.03%-96.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFGENFibroGen4.2927 of 5 stars3.35.00.04.70.63.30.6LYELLyell Immunopharma3.3048 of 5 stars2.83.00.00.03.35.01.3THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals2.4186 of 5 stars3.52.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGENFibroGen 2.50Moderate Buy$10.002,967.48% UpsideLYELLyell Immunopharma 1.50Reduce$1.00137.53% UpsideTHTXTheratechnologies 4.00Strong BuyN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$585.002,970.06% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, LYEL, THTX, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.002/20/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/14/2025THTXTheratechnologiesResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGENFibroGen$29.62M1.11N/AN/A($1.87) per share-0.17LYELLyell Immunopharma$61K2,038.32N/AN/A$2.60 per share0.16THTXTheratechnologies$88.67M1.43N/AN/A($0.45) per share-6.12TNXPTonix Pharmaceuticals$10.09M12.15N/AN/A$5,751.80 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGENFibroGen-$284.23M-$0.48N/AN/AN/A-67.66%N/A-36.17%N/ALYELLyell Immunopharma-$234.63M-$1.31N/AN/AN/A-323,792.09%-34.64%-30.02%N/ATHTXTheratechnologies-$23.96M-$0.08N/A39.36N/A-3.75%N/A-4.31%7/9/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)Latest FGEN, LYEL, THTX, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23N/AN/AN/A$2.55 millionN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 million3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFGENFibroGenN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGENFibroGenN/A1.281.16LYELLyell ImmunopharmaN/A13.4313.43THTXTheratechnologiesN/A1.080.97TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGENFibroGen72.71%LYELLyell Immunopharma66.05%THTXTheratechnologiesN/ATNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipFGENFibroGen3.07%LYELLyell Immunopharma25.10%THTXTheratechnologiesN/ATNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGENFibroGen570101.04 million98.78 millionOptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionableFGEN, LYEL, THTX, and TNXP HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.5% Higher - Here's WhyMay 7 at 3:40 PM | marketbeat.comTonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on MondayMay 7 at 8:12 AM | marketbeat.comGeode Capital Management LLC Purchases 1,855,907 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 6 at 3:10 AM | marketbeat.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest UpdateMay 5 at 3:17 PM | marketbeat.comTonix Pharmaceuticals Holding Corp Share Chat (TNXP.US)May 3, 2025 | lse.co.ukTonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual MeetingApril 29, 2025 | globenewswire.comTonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woesApril 28, 2025 | fiercebiotech.comTonix Pharmaceuticals present data on potential Mpox vaccine TNX-801April 26, 2025 | markets.businessinsider.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 7.99%April 24, 2025 | aaii.comTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025April 24, 2025 | globenewswire.comTonix Pharmaceuticals (TNXP) to Present at World Vaccine CongressApril 23, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Falls Despite Market UpturnApril 23, 2025 | gurufocus.comTonix Pharmaceuticals to Present at World Vaccine Congress Washington 2025 on Novel Mpox VaccineApril 16, 2025 | quiverquant.comTonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025April 16, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday?April 10, 2025 | insidermonkey.comTonix Pharmaceuticals, Makana to announce collaboration research agreementApril 9, 2025 | msn.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 10.75%April 9, 2025 | aaii.comTonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation StudiesApril 9, 2025 | globenewswire.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 18.09%April 8, 2025 | aaii.comWhat is Zacks Small Cap's Estimate for TNXP Q1 Earnings?April 8, 2025 | marketbeat.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...April 7, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, LYEL, THTX, and TNXP Company DescriptionsFibroGen NASDAQ:FGEN$0.33 +0.03 (+11.95%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.01 (+1.53%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Lyell Immunopharma NASDAQ:LYEL$0.42 +0.01 (+1.27%) Closing price 04:00 PM EasternExtended Trading$0.41 -0.01 (-3.09%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Theratechnologies NASDAQ:THTX$2.76 +0.02 (+0.55%) Closing price 03:59 PM EasternExtended Trading$2.73 -0.02 (-0.87%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Tonix Pharmaceuticals NASDAQ:TNXP$19.06 +0.18 (+0.93%) Closing price 03:59 PM EasternExtended Trading$18.96 -0.09 (-0.49%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
